Newly approved diabetes drug achieves record weight loss in clinical trials

A recently approved FDA-approved type 2 diabetes drug (T2D) has been reported to have reduced more than 20 percent of weight in obese individuals by giving the drug once every week. The SURMOUNT-1 study, a phase III trial led by researchers from Yale University testing the efficacy and safety of tirzepatide, found that obese participants …

Newly approved diabetes drug achieves record weight loss in clinical trials Read More »